vTv Therapeutics Announces Initiation of Study Evaluating TTP399's Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
Stock Information for vTv Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.